AbbVie: Arthritis, Juvenile trials

The registry lists 10 Arthritis, Juvenile studies with AbbVie as lead sponsor. 2 are open to participants now and 4 have results posted.

Phase 1 1Phase 3 4No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabRecruitingNCT06100744Phase 3
• Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingNCT05609630Phase 3
• Surveillance of Humira in Korean JIA PatientsCompletedNCT02141984Results posted
• Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic ArthritisCompletedNCT01412021Results posted
• A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related ArthritisCompletedNCT01166282Phase 3Results posted
• Active Juvenile Idiopathic Arthritis (JIA) Compassionate UseCompletedNCT00775437Phase 3Results posted
• An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)CompletedNCT05411211
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic ArthritisActive, not recruitingNCT03725007Phase 1
• A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)CompletedNCT03383263
• Juvenile Idiopathic Arthritis (JIA) RegistryCompletedNCT00783510